Welcome to our dedicated page for Thermo Fishr Sci SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Thermo Fisher Scientific Inc. (NYSE: TMO) files a wide range of documents with the U.S. Securities and Exchange Commission, and this page aggregates those SEC filings for investors tracking TMO. The company’s common stock and multiple series of senior notes are listed on the New York Stock Exchange, and its filings describe the terms, rankings and covenants of these securities, as well as material events affecting the business.
Recent Form 8‑K filings illustrate the types of information Thermo Fisher discloses. Several 8‑Ks detail public offerings of senior notes in U.S. dollars and euros, including maturities, interest payment schedules, redemption provisions, change‑of‑control protections and the use of proceeds for general corporate purposes such as acquisitions, debt repayment or refinancing, working capital, capital expenditures or equity repurchases. Other 8‑Ks report the completion of the acquisition of Solventum Corporation’s purification and filtration business and the signing of a definitive agreement to acquire Clario Holdings, Inc.
Thermo Fisher also uses 8‑K filings to communicate quarterly financial results, leadership transitions and organizational changes. For example, filings describe announcements of financial results for specific fiscal quarters, the planned retirement of the Senior Vice President and Chief Financial Officer and the appointment of a successor, and updates to the organizational structure and leadership team, including changes in executive roles.
On Stock Titan’s SEC filings page for TMO, users can access these current reports alongside other registered securities information, and benefit from AI‑powered summaries that explain key terms, highlight significant covenants, and clarify how new debt offerings, acquisitions, leadership changes or other material events may affect Thermo Fisher Scientific’s capital structure and corporate profile.
Michael D. Shafer, Executive Vice President of Thermo Fisher Scientific, filed a Form 4 disclosing four dispositions of the issuer's common stock on 08/28/2025. Each transaction is reported with Transaction Code F and a per-share price of $489.74. The reported share decreases are 145.051, 162.457, 176.478 and 114.106 shares, leaving a final beneficial ownership of 18,730.8026 shares after the last reported sale. The filing notes inclusion of 49.871 shares acquired under the company employee stock purchase plan on May 15, 2025. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Shafer on 09/02/2025. The document identifies Mr. Shafer as an officer (Executive Vice President) of the issuer.
Frederick M. Lowery, Executive Vice President of Thermo Fisher Scientific (TMO), reported multiple disposals of common stock on 08/28/2025 at a price of $489.74 per share. The Form 4 shows four separate disposition entries totaling 667.718 shares disposed (175.028 + 187.116 + 186.632 + 118.942) and remaining direct beneficial ownership reported in fractional amounts (14,860.0624; 14,672.9464; 14,486.3144; 14,367.3724 across lines). The filing also reports indirect holdings of 1,174.88 shares through a 401(k) plan and 5.036 shares via a limited liability company, with a disclaimer of beneficial ownership for the LLC position.
Michel Lagarde, Executive Vice President & COO of Thermo Fisher Scientific (TMO), reported multiple open-market sales on 08/28/2025. The Form 4 shows four dispositions totaling 961.203 shares sold at $489.74 per share (transaction code F). After these transactions, the report indicates Mr. Lagarde beneficially owns 23,479.909 shares. The filing was signed on behalf of Mr. Lagarde by an attorney-in-fact on 09/02/2025.
Joseph R. Holmes, VP & Chief Accounting Officer of Thermo Fisher Scientific (TMO), reported several equity transactions on Form 4 dated 08/28/2025–08/29/2025. The filing shows multiple dispositions on 08/28/2025 at $489.74 per share (totaling reductions of 37.977 shares when summing 8.512, 10.567, 10.86 and 7.045) and additional transactions on 08/29/2025 including an acquisition of 385 shares at $253.99 and two open-market sales of 100 shares at $492.615 and 285 shares at $492.633. Following these transactions, Holmes beneficially owned 2,318.9815 shares directly. The filing notes 54.846 shares were acquired under the issuer’s employee stock purchase plan on May 15, 2025, and that the 385-share option vested in four installments in 2020–2023.
Gianluca Pettiti, listed as Executive Vice President of Thermo Fisher Scientific (TMO), reported multiple dispositions of Common Stock on 08/28/2025. Four separate line items show sales (transaction code F) totaling 814.702 shares at $489.74 per share, with post-transaction beneficial ownership reported as 21,552.223 to 22,167.238 shares across the entries. The Form 4 is signed by an attorney-in-fact on 09/02/2025. The filing provides name, address, role, transaction dates, codes, quantities, price, and resulting ownership figures.
Thermo Fisher Scientific insider transaction: This Form 4 shows Lisa P. Britt, Sr. VP and Chief HR Officer, reported four dispositions of Thermo Fisher common stock on 08/28/2025. Each line records a transaction code "F" disposing of 81.229, 87.514, 96.7, and 63.339 shares at $489.74 per share. The reported beneficially owned share totals after each disposition are 16,142.357, 16,054.843, 15,958.143, and 15,894.804 shares, respectively. The form is signed by an attorney-in-fact on behalf of Ms. Britt on 09/02/2025. The filing is a routine Section 16 disclosure documenting insider sales; no derivative transactions or additional explanatory text are provided.
Thermo Fisher Scientific (TMO) Form 144 notice for a proposed sale of common stock. The filing shows 385 shares to be sold through Fidelity Brokerage Services with an approximate aggregate market value of $189,661.91 and an approximate sale date of 08/29/2025 on the NYSE. The filing reports 377,612,121 shares outstanding. The securities were listed as acquired on 08/29/2025 by exercise of an option granted 02/26/2019, and payment is indicated as cash. Several identifying fields such as the filer CIK/CCC and the named person for whose account the securities are to be sold are blank in the provided text, and no sales in the past three months are reported.
Marc N. Casper, Chairman & CEO of Thermo Fisher Scientific (TMO), reported option exercise and offsetting open-market sales executed under a 10b5-1 plan. He exercised a stock option to acquire 10,000 shares at an exercise price of $253.99 on 08/22/2025. On the same date he sold a total of 10,000 shares in multiple transactions at weighted-average prices within three reported ranges: approximately $500.00–$500.98, $501.05–$501.99, and $502.02–$502.37. Following these transactions his direct beneficial ownership is reported as 115,173.623 shares, and he also reports indirect holdings through trusts and entities totaling additional positions. The sales were made pursuant to a Rule 10b5-1 trading plan adopted April 28, 2025.
Form 144 notice for Thermo Fisher Scientific (TMO) shows a proposed sale of 10,000 common shares through Fidelity Brokerage Services with an aggregate market value of $5,009,587.68, and lists prior sales by the same seller during August 2025 totaling 18,496 shares for gross proceeds of $8,196,802.53. The filing states the 10,000 shares were acquired by option grant (original grant date 02/26/2019) and scheduled for sale and payment on 08/22/2025 for cash. The table lists the issuer’s outstanding shares as 377,612,121 and the planned execution on the NYSE. The filer certifies, by signing the notice, that they are not aware of undisclosed material adverse information and references Rule 10b5-1 procedures if applicable.
FAQ
What is the current stock price of Thermo Fishr Sci (TMO)?
What is the market cap of Thermo Fishr Sci (TMO)?
